Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors
Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors
复制标题
DOI：
10.3892/ijo.2011.1069
复制
发表时间：
2011-09-01
影响因子：
5.2
通讯作者：
Sano, Shigetoshi
中科院分区：
文献类型：
--
作者：
Ogawa, Yasuhiro;Kubota, Kei;Sano, Shigetoshi
基于直线加速器的放射治疗对恶性黑色素瘤、各种类型的肉瘤和大多数生长到几厘米或更长的局部晚期肿瘤几乎没有影响。这些肿瘤含有许多低氧癌细胞或大量抗氧化酶，因此对低线性能量转移辐射具有抗性。因此，有必要开发新的放射增敏剂来克服这些情况。我们之前开发了一种名为KORTUC I的新型酶靶向放射增敏治疗，该治疗使用3% w/v过氧化氢溶液浸泡的纱布。我们开发了一种新的放射增敏剂瘤内注射（KORTUC II），包括过氧化氢和透明质酸钠的组合。在提供完全知情的书面同意书后，52例患有不可切除或复发性肿瘤（53处病变）的患者入组KORTUC II试验。目前对52例不可切除或复发性肿瘤患者的研究表明，KORTUC II在瘤内注射时是安全的，耐受性良好，并可有效发挥放射增敏作用。由于这种放射增敏剂安全且比其他方法便宜，并且几乎可以应用于所有类型的低LET放射抗性肿瘤，因此它具有全球和立即使用的潜力。
Linear accelerator-based radiotherapy has little effect on tumors such as malignant melanoma, various types of sarcoma, and most locally-advanced neoplasms that have grown to several centimeters or more. These tumors contain many hypoxic cancer cells or large amounts of anti-oxidative enzymes, and are therefore resistant to low linear energy transfer radiation. Therefore, it was necessary to develop a new radiosensitizer to overcome these situations. We previously developed a new enzyme-targeting radiosensitization treatment named KORTUC I, which uses 3% w/v hydrogen peroxide solution-soaked gauze. We developed a new radiosensitizer for intratumoral injection (KORTUC II), comprising a combination of hydrogen peroxide and sodium hyaluronate. After providing a fully informed written consent, 52 patients with unresectable or recurrent neoplasms (53 lesions) were enrolled in the KORTUC II trial. The present study of 52 patients with unresectable or recurrent neoplasms showed that KORTUC II is safe when injected intratumorally, well tolerated, and can efficiently exert a radiation sensitizing effect. Because this radiosensitizer is safe and less expensive than other methods, and can be applied for almost every type of low-LET radioresistant neoplasm, it has potential for worldwide and immediate use.